共 40 条
[11]
Musher D.M., Alexandraki I., Graviss E.A., Et al., Bacteremic and nonbacteremic pneumococcal pneumonia, A prospective study. Medicine (Baltimore), 79, pp. 210-221, (2000)
[12]
Kadioglu A., Gingles N.A., Grattan K., Et al., Host cellularmmune response to pneumococcal lungnfectionn mice, Infect Immun, 68, pp. 492-501, (2000)
[13]
Boomer J.S., To K., Chang K.C., Et al., Immunosuppressionn patients who die of sepsis and multiple organ failure, JAMA, 306, pp. 2594-2605, (2011)
[14]
Hotchkiss R.S., Monneret G., Payen D., Sepsis-inducedmmunosuppression: from cellular dysfunctions tommunotherapy, Nat Rev Immunol, 13, pp. 862-874, (2013)
[15]
Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare-associated pneumonia, Am J Respir Crit Care Med, 171, pp. 388-416, (2005)
[16]
Mandell L.A., Wunderink R.G., Anzueto A., Et al., Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonian adults, Clin Infect Dis, 44, pp. S27-72, (2007)
[17]
Charlson M.E., Pompei P., Ales K.L., Et al., A new method of classifying prognostic comorbidityn longitudinal studies: development and validation, J Chronic Dis, 40, pp. 373-383, (1987)
[18]
Fine M.J., Auble T.E., Yealy D.M., Et al., A prediction rule todentify lowrisk patients with community-acquired pneumonia, N Engl J Med, 336, pp. 243-250, (1997)
[19]
Le Gall J.R., Lemeshow S., Saulnier F., A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study, JAMA., 270, pp. 2957-2963, (1993)
[20]
Lim W.S., van der Eerden M.M., Laing R., Et al., Defining community acquired pneumonia severity on presentation to hospital: annternational derivation and validation study, Thorax, 58, pp. 377-382, (2003)